Please login to the form below

Not currently logged in
Email:
Password:

Philadelphia chromosome positive acute lymphoblastic leukaemia

This page shows the latest Philadelphia chromosome positive acute lymphoblastic leukaemia news and features for those working in and with pharma, biotech and healthcare.

EMA to review safety of Ariad’s Iclusig

EMA to review safety of Ariad’s Iclusig

The PRAC also recommend that the product information be updated for Iclusig, which was approved in the EU in July to treat patients with chronic myeloid leukaemia (CML) and Philadelphia-chromosome ... positive acute lymphoblastic leukaemia (Ph+ ALL).

Latest news

  • Ariad cuts 160 jobs in US after Iclusig suspension Ariad cuts 160 jobs in US after Iclusig suspension

    The authorisations cover use of the drug to treat adults with advanced forms of chronic myeloid leukaemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL).

  • FDA suspends sale of Ariad’s cancer drug FDA suspends sale of Ariad’s cancer drug

    Iclusig linked to increased risk of blood clots. The US Food and Drug Administration (FDA) has asked Ariad to suspend sales of its leukaemia drug Iclusig as it continues to investigate ... accelerated phase, or blast phase CML or Philadelphia

  • Ariad tanks as Iclusig trial is halted on safety grounds Ariad tanks as Iclusig trial is halted on safety grounds

    The EPIC trial involved patients with newly-diagnosed chronic myeloid leukaemia (CML) and was stopped "in the interest of patient safety", said the company in a statement. ... accelerated phase, or blast phase CML or Philadelphia chromosome-positive

  • Ariad halts patient enrolment for cancer drug studies Ariad halts patient enrolment for cancer drug studies

    Iclusig (ponatinib) received early approval in the US last year for the treatment of advanced chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), under the proviso

  • Ariad gets EU green light for leukaemia drug Iclusig Ariad gets EU green light for leukaemia drug Iclusig

    The EC gave the go-ahead for Iclusig (ponatinib) as another treatment option for patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... Japan. Meanwhile, it is also focusing on

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    December 2012 for its use in two rare types of cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... As for the future of Iclusig in leukaemia, Ariad is keen to roll out the drug in

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Ariad founder Harvey Berger to retire as CEO and chairman Ariad founder Harvey Berger to retire as CEO and chairman

    Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,

  • Hugh Cole leaves Shire for Ariad Hugh Cole leaves Shire for Ariad

    This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics